To read more about these antibodies please refer to the following citation:
Haque F, Varlet P, Puntonet J, Storer L, Bountali A, Rahman R, Grill J, Carcaboso AM, Jones C, Layfield R, Jones C, Layfield R and Grundy RG. (2017) Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathologica Communications. 5; 45
Cambridge Research Biochemicals are world leaders in peptide synthesis (antigen peptides and other variants/ modifications) and antibody generation, with over 38 years of
industry expertise. Mutant specific anti-peptide antibodies are highly sought-after research tools for gaining knowledge and insight into target specific mutations.
These highly specific antibodies will soon be available via CRB’s partner brand DISCOVERY antibodies – click here to visit the website to browse in the meantime. If you would like to express an interest in this antibody, please email the DISCOVERY antibodies Team.